Traditional prognostic biomarkers such as CEA, CA19-9, and KRAS have been utilized to predict the likely course of disease progression in cancer, allowing physicians to personalize their patients’ treatments based on their cellular characteristics. This evidence concerns the gene CEACAM5 and cancer.